IMCR Immunocore Holdings plc ADRs

Immunocore is a pioneering, clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$47.56  -1.44 (-2.94%)
As of 02/26/2021 15:55:35 EST     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
ADRs
Small cap
Health Care
Biotechnology
United Kingdom

02/04/2021
8,985,507
358,883
$434,539,119
0.00%
SEC Edgar Online
20-F



Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-16.74
27.95
77.02
-167.00%
-460.21%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy